(BTAI) BioXcel Therapeutics - Overview
Stock: Sublingual Film, Phase 3, Oral Activator, Dementia Candidates
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 151% |
| Relative Tail Risk | -20.6% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.28 |
| Alpha | -95.63 |
| Character TTM | |
|---|---|
| Beta | 1.984 |
| Beta Downside | 1.471 |
| Drawdowns 3y | |
|---|---|
| Max DD | 99.78% |
| CAGR/Max DD | -0.86 |
Description: BTAI BioXcel Therapeutics December 23, 2025
BioXcel Therapeutics (NASDAQ:BTAI) leverages artificial-intelligence-driven drug discovery to build a pipeline in two therapeutic arenas-neuroscience and immuno-oncology-targeting high-unmet-need conditions in the United States.
The company’s first FDA-approved product, IGALMI, is a sublingual film for acute agitation in schizophrenia or bipolar I/II disorder. Its lead neuroscience candidate, BXCL501 (an oral dexmedetomidine film), is in Phase 3 trials for agitation across bipolar disorder, schizophrenia, Alzheimer’s disease, opioid-use disorder, alcohol-use disorder with PTSD, and acute stress disorder. In immuno-oncology, BXCL701, an oral innate-immune activator, has completed a Phase 1b/2a study in aggressive prostate, pancreatic, and other solid and liquid tumors. Additional early-stage assets (BXCL502-504) aim at apathy and aggression in dementia-related neuropsychiatric syndromes.
BioXcel partners with academic powerhouses-Columbia University, Yale University Medical School, and the University of North Carolina-to co-develop BXCL501, providing external validation of its AI-derived target selection and accelerating clinical timelines.
Key operating metrics (as of Q3 2024) include a cash runway of roughly $200 million, R&D spend representing ~45 % of total expenses, and a market-cap near $1.2 billion. The broader AI-enabled biotech sector has been outpacing the overall biotech index, with a 12-month average revenue multiple of ~8× versus ~5× for traditional peers, reflecting investor appetite for data-driven pipelines.
For a deeper, data-rich view of BioXcel’s valuation dynamics, you may find the analyst tools on ValueRay worth a quick look.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -68.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -1.30 > 0.02 and ΔFCF/TA 42.01 > 1.0 |
| NWC/Revenue: 877.5% < 20% (prev 976.9%; Δ -99.41% < -1%) |
| CFO/TA -1.30 > 3% & CFO -58.2m > Net Income -68.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.17 > 1.5 & < 3 |
| Outstanding Shares: last quarter (14.2m) vs 12m ago 435.8% < -2% |
| Gross Margin: -38.16% > 18% (prev 0.08%; Δ -3824 % > 0.5%) |
| Asset Turnover: 1.61% > 50% (prev 4.66%; Δ -3.05% > 0%) |
| Interest Coverage Ratio: -3.10 > 6 (EBITDA TTM -51.3m / Interest Expense TTM 16.6m) |
Altman Z'' -15.00
| A: 0.15 (Total Current Assets 44.4m - Total Current Liabilities 37.8m) / Total Assets 44.8m |
| B: -15.80 (Retained Earnings -707.5m / Total Assets 44.8m) |
| C: -1.10 (EBIT TTM -51.6m / Avg Total Assets 46.8m) |
| D: -5.29 (Book Value of Equity -707.5m / Total Liabilities 133.7m) |
| Altman-Z'' Score: -63.49 = D |
Beneish M 1.00
| DSRI: 132.2 (Receivables 131.0k/3000 , Revenue 752.0k/2.28m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.0 (AQ_t 0.0 / AQ_t-1 0.00) |
| SGI: 0.33 (Revenue 752.0k / 2.28m) |
| TATA: -0.22 (NI -68.2m - CFO -58.2m) / TA 44.8m) |
| Beneish M-Score: 103.6 (Cap -4..+1) = D |
What is the price of BTAI shares?
Over the past week, the price has changed by -5.66%, over one month by -13.79%, over three months by -15.73% and over the past year by -49.76%.
Is BTAI a buy, sell or hold?
- StrongBuy: 1
- Buy: 1
- Hold: 0
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the BTAI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 15.3 | 916.7% |
| Analysts Target Price | 15.3 | 916.7% |
| ValueRay Target Price | 1.7 | 14.7% |
BTAI Fundamental Data Overview February 05, 2026
P/B = 3.9656
Revenue TTM = 752.0k USD
EBIT TTM = -51.6m USD
EBITDA TTM = -51.3m USD
Long Term Debt = 92.3m USD (from longTermDebt, last quarter)
Short Term Debt = 17.0m USD (from shortTermDebt, last quarter)
Debt = 109.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 72.0m USD (from netDebt column, last quarter)
Enterprise Value = 106.3m USD (34.3m + Debt 109.3m - CCE 37.3m)
Interest Coverage Ratio = -3.10 (Ebit TTM -51.6m / Interest Expense TTM 16.6m)
EV/FCF = -1.83x (Enterprise Value 106.3m / FCF TTM -58.2m)
FCF Yield = -54.76% (FCF TTM -58.2m / Enterprise Value 106.3m)
FCF Margin = -7741 % (FCF TTM -58.2m / Revenue TTM 752.0k)
Net Margin = -9071 % (Net Income TTM -68.2m / Revenue TTM 752.0k)
Gross Margin = -38.16% ((Revenue TTM 752.0k - Cost of Revenue TTM 1.04m) / Revenue TTM)
Gross Margin QoQ = 12.24% (prev 10.83%)
Tobins Q-Ratio = 2.37 (Enterprise Value 106.3m / Total Assets 44.8m)
Interest Expense / Debt = 4.00% (Interest Expense 4.37m / Debt 109.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -40.8m (EBIT -51.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.17 (Total Current Assets 44.4m / Total Current Liabilities 37.8m)
Debt / Equity = -1.23 (negative equity) (Debt 109.3m / totalStockholderEquity, last quarter -88.9m)
Debt / EBITDA = -1.40 (negative EBITDA) (Net Debt 72.0m / EBITDA -51.3m)
Debt / FCF = -1.24 (negative FCF - burning cash) (Net Debt 72.0m / FCF TTM -58.2m)
Total Stockholder Equity = -95.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -145.6% (out of range, set to none)
RoE = 71.83% (negative equity) (Net Income TTM -68.2m / Total Stockholder Equity -95.0m)
RoCE = 1938 % (out of range, set to none) (EBIT -51.6m / Capital Employed (Equity -95.0m + L.T.Debt 92.3m))
RoIC = -354.5% (out of range, set to none) (NOPAT -40.8m / Invested Capital 11.5m)
WACC = 5.57% (E(34.3m)/V(143.6m) * Re(13.23%) + D(109.3m)/V(143.6m) * Rd(4.00%) * (1-Tc(0.21)))
Discount Rate = 13.23% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 177.7%
Fair Price DCF = unknown (Cash Flow -58.2m)
EPS Correlation: -16.71 | EPS CAGR: -14.71% | SUE: -1.70 | # QB: 0
Revenue Correlation: 30.79 | Revenue CAGR: 58.81% | SUE: -0.27 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.66 | Chg30d=+0.060 | Revisions Net=+1 | Analysts=3
EPS next Year (2026-12-31): EPS=-2.78 | Chg30d=+0.265 | Revisions Net=+0 | Growth EPS=+58.5% | Growth Revenue=+187.9%